During the past decade, Elisabethinen Hospital Linz conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 18 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 11 clinical trials were completed. i.e. 183.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Elisabethinen Hospital Linz" #1 sponsor was "Celgene" with 4 trials, followed by "AOP Orphan Pharmaceuticals AG" with 3 trials sponsored, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials sponsored, "Astellas Pharma Inc" with 2 trials sponsored and "Boehringer Ingelheim" with 2 trials sponsored. Other sponsors include 26 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Elisabethinen Hospital Linz" #1 collaborator was "Elisabethinen Hospital" with 2 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "Democritus University of Thrace" with 1 trials as a collaborator and "Erasmus Medical Center" with 1 trials as a collaborator. Other collaborators include 14 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Elisabethinen Hospital Linz" are "Pulmonary Arterial Hypertension" (4 trials), "Atrial Fibrillation" (3 trials), "Heart Failure" (3 trials), "Multiple Myeloma" (3 trials) and "Polycythemia Vera" (3 trials). Many other conditions were trialed in "Elisabethinen Hospital Linz" in a lesser frequency.

Most popular intervention types in "Elisabethinen Hospital Linz" are "Drug" (28 trials), "Other" (8 trials), "Device" (7 trials), "Procedure" (5 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Azacitidine" (2 trials), "FK463" (2 trials), "Neramexane mesylate" (2 trials) and "Sotatercept" (2 trials). Other intervention names were less common.

The vast majority of trials in "Elisabethinen Hospital Linz" are 44 trials for "All" genders.

Currently, there are NaN active trials in "Elisabethinen Hospital Linz". undefined are not yet recruiting, 2 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Elisabethinen Hospital Linz, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Elisabethinen Hospital Linz, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 6 trials that are defined as “Not Applicable".